| Completed | A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability Healthy Volunteers | EARLY_Phase 1 | 2020-10-26 |
| Completed | Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 Autoimmune Diseases, Fibrosis | Phase 1 | 2019-04-05 |
| Completed | Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Vo Drug-drug Interaction, Autoimmune Diseases, Fibrotic Disease | Phase 1 | 2018-04-09 |
| Completed | A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Rec Polycystic Kidney, Autosomal Recessive | Phase 1 | 2017-08-24 |
| Completed | A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With M Chronic Plaque Psoriasis | Phase 2 | 2016-09-14 |
| Completed | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma Glioblastoma, Recurrent Glioblastoma, Brain Tumor | Phase 2 | 2016-06-01 |
| Completed | A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis | Phase 2 | 2016-05-26 |
| Terminated | Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD01 Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | 2015-12-25 |
| Completed | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases | Phase 2 | 2015-11-01 |
| Completed | Bioavailability of Belumosudil (KD025) in Healthy Male Subjects Bioavailability | Phase 1 | 2015-09-01 |
| Completed | Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy Psoriasis Vulgaris | Phase 2 | 2014-12-01 |
| Terminated | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1 / Phase 2 | 2014-05-01 |
| Completed | A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Psoriasis Vulgaris | Phase 2 | 2014-04-01 |
| Terminated | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- Carcinoma, Non-Small-Cell Lung | Phase 3 | 2011-12-14 |
| Withdrawn | Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected Wi Hepatitis C | — | 2009-08-01 |
| Completed | Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlo Carcinoma, Non-Small-Cell Lung | Phase 2 | 2007-05-01 |
| Terminated | Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Hepatitis C | Phase 4 | 2007-02-01 |
| Completed | Study of XL647 Administered Orally Daily to Patients With Solid Tumors Cancer | Phase 1 | 2006-07-01 |
| Completed | Study of XL647 in Subjects With Non-Small-Cell Lung Cancer Non-small-cell Lung Cancer | Phase 2 | 2006-07-01 |
| Completed | Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors Cancer | Phase 1 | 2004-06-01 |